本文關(guān)鍵詞：我國醫(yī)藥制造業(yè)技術(shù)創(chuàng)新效率及其影響因素研究　出處：《廣東藥科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 醫(yī)藥制造業(yè) 技術(shù)創(chuàng)新 效率

【摘要】：醫(yī)藥制造業(yè)是一個以技術(shù)創(chuàng)新為發(fā)展原動力的行業(yè),具備一定的創(chuàng)新能力才能在世界市場上占得先機。在當(dāng)今世界激烈角逐的市場環(huán)境下,技術(shù)創(chuàng)新能力的競爭已不再是單純的人力、物力資源投入多少的較量。如何在現(xiàn)有投入下實現(xiàn)最大產(chǎn)出或保持產(chǎn)出不變的情況下投入最小,即效率問題,才是幫助制藥企業(yè)實現(xiàn)利潤最大化、提高醫(yī)藥制造業(yè)技術(shù)創(chuàng)新能力和水平的關(guān)鍵。因此,本文以創(chuàng)新效率的測算為基礎(chǔ),從國內(nèi)目前的政策環(huán)境出發(fā),探索能夠優(yōu)化創(chuàng)新投入結(jié)構(gòu)的有效途徑,有助于針對性的調(diào)整資源配置,使得效率改進工作更加富有針對性。本文在回顧國內(nèi)外相關(guān)研究的基礎(chǔ)上,提出以研發(fā)人員FTE(Full Time Equivalent,折合全時當(dāng)量,縮寫FTE)、研發(fā)經(jīng)費內(nèi)部支出、根據(jù)技術(shù)更新的常規(guī)路徑所確定的指標技術(shù)改造、引進以及消化吸收所花費的支出為醫(yī)藥制造業(yè)技術(shù)創(chuàng)新投入,新產(chǎn)品銷售收入以及專利申請數(shù)為技術(shù)創(chuàng)新產(chǎn)出的3投入2產(chǎn)出指標體系。利用Deap2.1軟件對我國24個省市及化學(xué)藥品、中成藥品和生物藥品,這三大行業(yè)的醫(yī)藥制造業(yè)的創(chuàng)新效率進行評價。根據(jù)效率測度結(jié)果,以省域為研究對象,運用Eviews6.0軟件使用面板數(shù)據(jù)模型對作用于創(chuàng)新效率的各種原因進行分析�；趯π仕郊白饔糜谒母黝愐蛩販y算,本文得出結(jié)論:研發(fā)資金投入、政府支持力度、新產(chǎn)品需求度所產(chǎn)生的作用力是正向的;研發(fā)人員投入、企業(yè)規(guī)模、外商投資對創(chuàng)新效率的影響負向的,這些因素的增加或擴大會阻礙創(chuàng)新效率的提高。據(jù)此,本文在分析制藥水平領(lǐng)先的美國、日本及與我國醫(yī)藥產(chǎn)業(yè)發(fā)展路徑相似的印度的創(chuàng)新發(fā)展模式的基礎(chǔ)上,提出如下幾點建議:(1)加強研發(fā)資金投入,仿創(chuàng)結(jié)合積累資本;(2)充分發(fā)揮研發(fā)人員效用,減少人力資源閑置;(3)加大政府資金投入,加強政府財政政策支持,同時強化專利保護政策;(4)建立以市場為導(dǎo)向的新藥研發(fā)決策程序;(5)統(tǒng)籌對外開放和市場保護。
[Abstract]:Pharmaceutical manufacturing industry is a technology innovation as the driving force of the industry, with a certain degree of innovation in the world market in order to occupy the first opportunity, in today's fierce competition in the world market environment. The competition of technological innovation ability is no longer a simple contest of manpower and material resources. How to achieve the maximum output under the existing input or to keep the output unchanged is the problem of efficiency. It is the key to help pharmaceutical enterprises to maximize profits and improve the technological innovation ability and level of pharmaceutical manufacturing industry. Therefore, based on the measurement of innovation efficiency, this paper starts from the current domestic policy environment. To explore an effective way to optimize the structure of innovation input, help to adjust the allocation of resources, and make the efficiency improvement more targeted. This paper reviews the relevant research at home and abroad. It is proposed that FTE(Full Time equivalent, abbreviated as FTE(Full Time equivalent, be used as the internal expenditure of R & D funds. According to the technical transformation of the indicators determined by the conventional path of technology renewal, the expenditure incurred by the introduction and absorption of the technical innovation investment for the pharmaceutical manufacturing industry. The new product sales income and patent application number are three input-output index system of technological innovation output. Using Deap2.1 software, 24 provinces and cities and chemicals, traditional Chinese patent medicine and biological drugs are analyzed. The innovation efficiency of pharmaceutical manufacturing industry in these three industries is evaluated. According to the result of efficiency measurement, the province is the research object. Using the Eviews6.0 software panel data model to analyze the various reasons for the efficiency of innovation. Based on the level of efficiency and the various factors acting on it. The conclusion of this paper is as follows: the influence of R & D investment, government support and demand degree of new products is positive; The influence of R & D personnel investment, enterprise size and foreign investment on innovation efficiency is negative. The increase or expansion of these factors will hinder the improvement of innovation efficiency. On the basis of the innovative development model of Japan and India, which is similar to China's pharmaceutical industry development path, this paper puts forward the following suggestions: strengthening R & D investment, combining imitation with creation to accumulate capital; 2) give full play to the utility of R & D personnel and reduce the idle human resources; (3) increasing government investment, strengthening government financial policy support, and strengthening patent protection policy at the same time; Establishing a market-oriented decision-making process for new drug research and development; 5) to coordinate opening up to the outside world and market protection.
【學(xué)位授予單位】：廣東藥科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：F426.72;F273.1

【參考文獻】

相關(guān)期刊論文 前10條

1 方大春;張凡;芮明杰;;我國高新技術(shù)產(chǎn)業(yè)創(chuàng)新效率及其影響因素實證研究——基于面板數(shù)據(jù)隨機前沿模型[J];科技管理研究;2016年07期

2 張學(xué)芬;章家清;;我國醫(yī)藥制造業(yè)技術(shù)創(chuàng)新效率影響因素實證研究[J];現(xiàn)代商貿(mào)工業(yè);2016年02期

3 郭丹丹;馮國忠;;我國大中型醫(yī)藥制造企業(yè)研發(fā)投入影響因素的實證分析[J];中國藥事;2015年05期

4 池仁勇;劉娟芳;張宓之;李瑜娟;;中低技術(shù)產(chǎn)業(yè)創(chuàng)新效率研究——基于我國大中型工業(yè)企業(yè)面板數(shù)據(jù)的實證[J];科技進步與對策;2014年16期

5 李林;傅慶;;產(chǎn)學(xué)研主體創(chuàng)新效率對區(qū)域創(chuàng)新的影響研究[J];科技進步與對策;2014年05期

6 陳冰;吉生保;;中國醫(yī)藥行業(yè)上市公司的績效評價及影響因素——基于面板數(shù)據(jù)的DEA-Tobit實證研究[J];中央財經(jīng)大學(xué)學(xué)報;2013年08期

7 馬瀾;;我國醫(yī)藥制造業(yè)創(chuàng)新能力的影響因素分析[J];科技管理研究;2012年16期

8 張繼輝;邵蓉;;中國醫(yī)藥研發(fā)資源配置效率評價研究——基于DEA[J];現(xiàn)代商貿(mào)工業(yè);2012年13期

9 高小s，

本文編號：1414971